These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697 [TBL] [Abstract][Full Text] [Related]
24. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Venalis P; Lundberg IE Rheumatology (Oxford); 2014 Mar; 53(3):397-405. PubMed ID: 23970542 [TBL] [Abstract][Full Text] [Related]
25. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878 [TBL] [Abstract][Full Text] [Related]
26. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690 [TBL] [Abstract][Full Text] [Related]
27. T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. Houtman M; Ekholm L; Hesselberg E; Chemin K; Malmström V; Reed AM; Lundberg IE; Padyukov L Arthritis Res Ther; 2018 Aug; 20(1):188. PubMed ID: 30157932 [TBL] [Abstract][Full Text] [Related]
29. Polymyositis and dermatomyositis - challenges in diagnosis and management. Yang SH; Chang C; Lian ZX J Transl Autoimmun; 2019 Dec; 2():100018. PubMed ID: 32743506 [TBL] [Abstract][Full Text] [Related]
30. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. Confalonieri P; Bernasconi P; Megna P; Galbiati S; Cornelio F; Mantegazza R J Neuropathol Exp Neurol; 2000 Feb; 59(2):164-9. PubMed ID: 10749105 [TBL] [Abstract][Full Text] [Related]
31. Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon. Patwardhan A; Spencer CH Pediatr Rheumatol Online J; 2019 Aug; 17(1):56. PubMed ID: 31429786 [TBL] [Abstract][Full Text] [Related]
32. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Walsh RJ; Kong SW; Yao Y; Jallal B; Kiener PA; Pinkus JL; Beggs AH; Amato AA; Greenberg SA Arthritis Rheum; 2007 Nov; 56(11):3784-92. PubMed ID: 17968926 [TBL] [Abstract][Full Text] [Related]
33. Human β-defensin-3 correlates with muscle fibre degeneration in idiopathic inflammatory myopathies. Güttsches AK; Jacobsen F; Theiss C; Rittig A; Rehimi R; Kley RA; Vorgerd M; Steinstraesser L Innate Immun; 2014 Jan; 20(1):49-60. PubMed ID: 23608825 [TBL] [Abstract][Full Text] [Related]
34. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Guo X; Higgs BW; Rebelatto M; Zhu W; Greth W; Yao Y; Roskos LK; White WI Rheumatology (Oxford); 2014 Apr; 53(4):686-95. PubMed ID: 24357810 [TBL] [Abstract][Full Text] [Related]
35. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Dourmishev LA Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112 [TBL] [Abstract][Full Text] [Related]
36. Characterised intron retention profiles in muscle tissue of idiopathic inflammatory myopathy subtypes. Xiao Y; Xie S; Li HD; Liu Y; Zhang H; Zuo X; Zhu H; Li Y; Luo H Ann Rheum Dis; 2024 Jun; 83(7):901-914. PubMed ID: 38302260 [TBL] [Abstract][Full Text] [Related]